Impact of neoadjuvant chemotherapy on rate of tissue expander/implant loss and progression to successful breast reconstruction following mastectomy
To access this article, please choose from the options below
Supported in part by grants from Novartis Pharmaceutical Corp. East Hanover, NJ and Pfizer, Inc., Peapack, NJ.
PII: S0002-9610(08)00476-5
doi:10.1016/j.amjsurg.2008.06.016
© 2008 Elsevier Inc. All rights reserved.
